Adagene doses first patient in Phase 1 trial of ADG138 for HER2-positive solid tumors
ADAG•Adagene dosed the first patient in a Phase 1 trial of ADG138 for HER2-positive advanced solid tumors; the study will assess safety and preliminary efficacy and establish a recommended Phase 2 dose.
1. Trial begins
The Phase 1 trial will assess safety and preliminary efficacy in heavily pretreated patients. Adagene said preclinical results showed antitumor activity, including in Enhertu-resistant models, and reduced cytokine release compared with an unmasked T-cell engager.




